Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm phase 3b study of subcutaneous Hemlibra in infants with severe hemophilia A without FVIII inhibitors
MOH_2021-04-11_009701Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jan 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Roche. Started Jan 2021; status: recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on MOH_2021-04-11_009701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-11_009701.